KALYDECO Drug Insight and Market Forecast - 2032

“This “KALYDECO Drug Insight and Market Forecast - 2032” report provides comprehensive insights about KALYDECO for Cystic Fibrosis in the six major markets. A detailed picture of the KALYDECO for cystic fibrosis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the KALYDECO for cystic fibrosis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KALYDECO market forecast analysis for cystic fibrosis in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in cystic fibrosis.

Drug Summary

KALYDECO is a Chloride Transport Assay in Fisher Rat Thyroid (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel open probability (or gating) of CFTR protein located at the cell surface. The overall level of ivacaftor-mediated CFTR chloride transport is dependent on the amount of CFTR protein at the cell surface and how responsive a particular mutant CFTR protein is to ivacaftor potentiation.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the KALYDECO description, mechanism of action, dosage and administration, research and development activities in cystic fibrosis.
• Elaborated details on KALYDECO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the KALYDECO research and development activities in cystic fibrosis across the United States and Europe.
• The report also covers the patents information with expiry timeline around KALYDECO.
• The report contains forecasted sales of KALYDECO for cystic fibrosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for cystic fibrosis.
• The report also features the SWOT analysis with analyst views for KALYDECO in cystic fibrosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KALYDECO Analytical Perspective

In-depth KALYDECO Market Assessment

This report provides a detailed market assessment of KALYDECO for cystic fibrosis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.

KALYDECO Clinical Assessment

The report provides the clinical trials information of KALYDECO for cystic fibrosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for cystic fibrosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KALYDECO dominance.
• Other emerging products for cystic fibrosis are expected to give tough market competition to KALYDECO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KALYDECO in cystic fibrosis.
• The in-depth analysis of the forecasted sales data of KALYDECO from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KALYDECO in cystic fibrosis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of KALYDECO?
• What is the clinical trial status of the study related to KALYDECO in cystic fibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KALYDECO development?
• What are the key designations that have been granted to KALYDECO for cystic fibrosis?
• What is the forecasted market scenario of KALYDECO for cystic fibrosis?
• What are the forecasted sales of KALYDECO in the six major countries, including the United States and Europe (Germany, France, Italy, Spain, and the United Kingdom)?
• What are the other emerging products available and how are these giving competition to KALYDECO for cystic fibrosis?
• Which are the late-stage emerging therapies under development for the treatment of cystic fibrosis?

This product will be delivered within 2 business days.